RESUMO
"Disease modification" in axial spondyloarthritis (axSpA) seeks to not only alleviate clinical symptoms but also alter the disease's natural course by impeding new bone formation. Recent years have witnessed the effectiveness of treatments, including biologics and nonsteroidal anti-inflammatory drugs, in managing axSpA symptoms. Emerging evidence points toward their potential impact on slowing structural disease progression. This comprehensive review centers on the pivotal role of inhibiting new bone formation in axSpA disease modification. It delves into the significance of imaging techniques for assessing disease progression and explores the disease-modifying properties of available axSpA treatments, encompassing NSAIDs, TNF inhibitors, IL-17 inhibitors, and JAK inhibitors. This article offers valuable insights into the evolving landscape of disease modification strategies in axial spondyloarthritis, highlighting the multifaceted approaches used to attain these objectives.
Assuntos
Antirreumáticos , Espondiloartrite Axial , Espondilartrite , Espondilite Anquilosante , Humanos , Espondilite Anquilosante/tratamento farmacológico , Antirreumáticos/uso terapêutico , Espondilartrite/diagnóstico , Espondilartrite/tratamento farmacológico , Anti-Inflamatórios não Esteroides/uso terapêutico , Progressão da DoençaRESUMO
Axial spondyloarthritis (axSpA) is a chronic inflammatory disorder that primarily affects the axial skeleton, including the spine and sacroiliac joints.1 It encompasses both nonradiographic axSpA (nr-axSpA) and radiographic axSpA (also known as ankylosing spondylitis [AS]), the latter characterized by radiographic evidence of sacroiliitis.2.
